Jasper, Avrobio to collaborate in gene therapy trials

By The Science Advisory Board staff writers

November 9, 2021 -- Jasper Therapeutics and Avrobio have entered a nonexclusive research collaboration to evaluate Jasper's anti-CD117 monoclonal antibody (mAb) in clinical trials.

The mAb, JSP191, will be tested as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of Avrobio's investigational ex vivo lentiviral gene therapies.

JSP191 is a conditioning agent that blocks stem cell factor receptor signaling, which clears hematopoietic stem cells from bone marrow and leaves an empty space for donor or genetically modified transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients.

In addition, Jasper is launching two clinical trials to test JSP191 in patients with myelodysplastic syndromes/acute myeloid leukemia and severe combined immunodeficiency.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here